摘要
目的探讨精神分裂症患者外周血中多药耐药基因C1236T位点的基因多态性与帕利哌酮缓释片疗效的相关性。方法对68例精神分裂症患者予以口服帕利哌酮缓释片治疗，观察6周。采用阳性与阴性症状量表、简明精神病量表评定临床疗效，个人和社会功能量表评定社会功能。治疗后根据阳性与阴性症状量表总分减分率（≥50％为有效）将患者分为有效组和无效组。采用聚合酶链反应一限制性片段长度多态性分析技术检测其多药耐药基因C1236T位点的基因型。将有效组和无效组的基因型进行对比分析。结果本组患者治疗6周后阳性与阴性症状量表总分及各因子分、简明精神病量表总分均较治疗前显著下降，个人与社会功能量表总分较治疗前显著升高（P〈O．01）。有效组与无效组基因型频率比较差异无显著性（P〉0．05）。结论帕利哌酮缓释片治疗精神分裂症疗效显著，未发现多药耐药基因C1236T位点的多态性与帕利哌酮缓释片的疗效有关。
Objective To explore the correlation between the C1236T polymorphisms of multidrug resist- ance 1 gene （MDR1） in peripheral blood and the efficacy of paliperidone extended-release tablets. Methods Sixty-eight schizophrenia patients were treated with oralpaliperidone extended-release tablets for 6 weeks. Efficacies were assessed with the Positive and Negative Syndrome Scales （PANSS）and Brief Psy- chiatric Rating Scale （BPRS） and social functions with the Personal and Social Performance scale（PSP）. According to the reducing rate of the PANSS total score patients were divided into responsive （reducing rate was ~ 50%） and unresponsive group. C1236T genotypes of the MDR1） were detected using polymer- ase chain reaction restriction fragment length polymorphism （PCR-RFLP）. Genotypes were contrastively analyzed between responsive and unresponsive group. Results After 6 week treatment their total and each factor score of the PANSS and total score of the BPRS lowered more significantly and total score of the PSP heightened compared with pretreatment （P〈0.01）. There were no marked differences in genotypic frequencies between responsive and unresponsive group （P 〉 0. 05）. Conclusion Paliperidone extended-release tablets are effective in schizophrenia, the correlation between the C1236T polymorphisms of the MDR1 and the efficacy of paliperidone extended-release tablets isn＇t found.
出处
《临床心身疾病杂志》
CAS
2016年第2期5-8,共4页
Journal of Clinical Psychosomatic Diseases
基金
广东省科技计划项目（编号20138021800046）
广东省自然科学基金资助项目（编号9151503102000013）
